Core Concepts In EP for the Allied Professional is designed to serve Allied Professionals (APs) in the EP community. It is intended to be an indispensable tool for providing fundamentally sound EP knowledge for APs.

This course will have over 20 recorded didactic lectures delivered by leading experts covering:    

•                     Bradyarrhythmias

•                     CIEDS

•                     General Concepts

•                     Tachyarrhythmias

•                     Special Topics

• Discuss safety and quality improvement in the EP lab
• Discuss shared medical decision making
• Understand the anatomy and physiology associated with bradyarrhythmia
• Review CIED remote monitoring and remote interrogation concepts
• Recognize the clinical factors in patients that are important in influencing risk of complications and risk of ablation failure.
• Understand special considerations for adults with congenital heart disease (e.g., limited access, common arrhythmias of specific CHD lesions)
• Understand the inheritance pattern and associated channelopathy of inherited arrhythmias
• Understand medical/device therapy indications and indications for advanced therapies for hypertrophic CM

Akash R. Patel, MD, FHRS, CEPS-P

UCSF Benioff Children`s Hospital | Pediatric and Congenital Electrophysiologist

Alessio Gasperetti, MD

Johns Hopkins University | Postdoc/Advanced Degree Student

Amayrah Yaeger, BSN, RN

Hospital of the University of Pennsylvania | Remote Monitoring Clinic Coordinator

Andrew D. Beaser, MD

University of Chicago | Electrophysiologist

Artur Fedorowski, MD, PhD

Karolinska University Hospital, Stockholm, Sweden | Associate Professor

Brian Long, BS, BSN, MBA

Emory University Healthcare | Clinical Staff Nurse

Brian Olshansky, MD, FHRS, CCDS

Mercy Hospital - North Iowa | Electrophysiologist

Brynn E. Dechert-Crooks, APN, FHRS, CCDS

C.S. Mott Children’s Hospital | Nurse Practitioner

David Bradley, MD, FHRS, CEPS-P

Univerity of Michigan - Mott Children`s Hospital | Director of Electrophysiology

David Lin, MD, FHRS

University of Pennsylvania | Associate Professor of Medicine

Edward Walsh, MD, FHRS, CCDS, CEPS-P

Boston Children`s Hospital | Associate Chief of Cardiology for Clinical Affairs

Edward P. Gerstenfeld, MD, FHRS

University of California, San Francisco I Professor

Elizabeth S. Kaufman, MD, FHRS

MetroHealth Medical Centre | Professor of Medicine

Emilie Sauser, APN, FNP

University of Chicago Medical Center | Nurse Practitioner

Erin Flatley, BSN, MSN, NP

University of California San Francisco | Nurse Practitioner

Frederic Sacher, MD, PhD

LIRYC Institute/ Bordeaux University | Cardiologist

Heather M. MacLeod, MS

SDY Case Registry | Genetic Counselor

Jackson Liang, DO

University of Michigan | Assistant Professor

Jennifer Sobacki, PAC

University of Chicago | Physician Assistant Specialist

Jeremy P. Moore, MD, MS, FHRS, CCDS, CEPS-P

UCLA Medical Center | Physician

Jonathan Walter Dukes, MD

Community Memorial Hospital | Physician

Jorge Romero, MD, FHRS

Brigham and Women’s Hospital - Harvard Medical School | Director

Lauren Ashley Rousseau, PAC, CCDS

Brigham and Women’s Hospital - Harvard Medical School | Physician Assistant

Laurie Racenet, MSN, FNP, FHRS, CEPS, CCDS

Alaska Heart and Vascular Institute | Nurse Practitioner

L. Lee Eckhardt, MD, FHRS

University of Wisconsin, School of Medicine | Associate Professor of Medicine

Linda K. Ottobani, PhD, CNS, FHRS, CCDS

Stanford Healthcare | Clinical Nurse Specialist

Marina Cerrone, MD

NYU School of Medicine | Assistant Professor

Martin Maron, MD

Tufts - New England Medical Center | Assistant Professor of Medicine

Matthew W. Martinez, MD

Mayo Clinic College of Medicine | Physician

Melissa R. Brown, PAC, FHRS, CCDS

Emory Cardiology | Physician Assistant

Melissa Olen, MSN

Nicklaus Children`s Hospital | Electrophysiology Nurse Pracitioner

Melissa Robinson, MD, FHRS, CCDS

University of Washington | Clinical Associate Professor

Melvin Scheinman, MD, FHRS

University of California - San Francisco | Professor of Medicine

Michael John Ackerman, MD, PhD

Mayo Clinic – Rochester | Genetic Cardiologist

Michele Brignole, MD

Ospedali del Tigullio | Physician

Miguel A. Leal, MD, FHRS

University of Wisconsin | Physician

Mitchell I. Cohen, MD, FHRS, CCDS, CEPS-P

Inova Children’s Hospital | Co-Director Inova Children's Heart Center

Nicole Haupert, NP

UCSF Benioff Children's Hospital | Pediatric Electrophysiology Nurse Practitioner

Patricia L Arscott, MS, CGC

University of Michigan | Genetic Counselor

Peter J. Schwartz, MD

Istituto Auxologico Italiano IRCCS | Professor of Cardiology

Philippe Maury, MD

Hopital Rangueil Toulouse | Doctor of Medicine

Rakesh Gopinathannair, MA, MD, FHRS

Kansas City Heart Rhythm Institute | Director of Cardiac Electrophysiology

Raul Weiss, MD, FHRS

Ohio State University | Physician

Reginald T. Ho, MD, FHRS

Thomas Jefferson University Hospital | Physician

Richard Sutton, DSC, MBBS, FHRS

Imperial College | Professor

Robert Hipp, MBA, MS, PA

University of Pennsylvania | Physician Assistant

Robert D. Schaller, DO, FHRS

University of Pennsylvania | Cardiac Electrophysiologist

Ryan Cunnane, MD

University of Michigan | Assistant Professor

Scott Cox, PAC

Main Line Health System | Physician Assistant

Sharon M. Holloway, ACNP

University of Chicago Hospital | Nurse Practitioner

Shelley Zieroth, MD

SBH Heart Failure and Transplant Clinics | Cardiologist

Steve Ommen, MD

Mayo Clinic College of Medicine | Physician

Susan Turpin, MS, CPNP-AC, CNS, CCDS

UCSF Benioff Children’s Hospital | Pediatric Nurse Practitioner

T. Jennifer Walker, MSN, ANP

University of North Carolina | Nurse Practitioner

Tara Parham, DNP

University of Pennsylvania | Nurse Practitioner

Wendy S. Tzou, MD, FHRS

University of Colorado Denver | Electrophysiologist

Win-Kuang Shen, MD, FHRS

Mayo Clinic College of Medicine, Mayo Clinic Arizona | Professor of Medicine

Zaid Aziz, MD

University of Chicago | Assistant Professor

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

• Advertising, marketing, or communication firms whose clients are ineligible companies
• Bio-medical startups that have begun a governmental regulatory approval process
• Compounding pharmacies that manufacture proprietary compounds
• Device manufacturers or distributors
• Diagnostic labs that sell proprietary products
• Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
• Manufacturers of health-related wearable products
• Pharmaceutical companies or distributors
• Pharmacy benefit managers
• Reagent manufacturers or sellers

All relevant financial relationships have been mitigated.

Planners:

P. Aziz: No relevant financial relationships with ineligible companies to disclose.
S. Cox: Honoraria/Speaking/Consulting Fee: ScottCare, Inc.
E. Daoud: Fellowship Support: Biotronik, Medtronic, Biosense Webster, Inc., Boston Scientific, Abbott. Research (Contracted Grants for PIs and Named Investigators Only): Abbott, Biosense Webster, Inc. Ownership/Partnership/Principal: S4 Medical
C. DeSimone: No relevant financial relationships with ineligible companies to disclose.
M. Lloyd: Honoraria/Speaking/Consulting Fee: Boston Scientific, Medtronic
R. Mullins: No relevant financial relationships with ineligible companies to disclose.
H. Nayak: Honoraria/Speaking/Consulting Fee: Pfizer, Inc., Bristol-Myers Squibb, Boston Scientific, Abbott, Spectranetics Corporation, Aziyo Biologics, Sanofi. Research (Contracted Grants for PIs and Named Investigators Only): Philips
L.K. Racenet: No relevant financial relationships with ineligible companies to disclose.
J. Schaeffer: Honoraria/Speaking/Consulting Fee: CHART Healthcare Academy
T. Trela: No relevant financial relationships with ineligible companies to disclose.
E. Zado: No relevant financial relationships with ineligible companies to disclose.


Faculty:

M. J. Ackerman: Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Daiichi Sankyo, UpToDate, ARMGO Pharma, LQT Therapeutics, Abbott, Bristol-Myers Squibb. Research (Contracted Grants for PIs and Named Investigators Only): LQT Therapeutics. Intellectual Property Rights: AliveCor, Anumana, Pfizer, Inc.
P. L. Arscott: Speakers' Bureau: Ambry Genetics
Z. Aziz: Honoraria/Speaking/Consulting Fee: Biotronik
A. D. Beaser: No relevant financial relationships with ineligible companies to disclose.
D. Bradley: No relevant financial relationships with ineligible companies to disclose.
M. Brignole: No relevant financial relationships with ineligible companies to disclose.
M. I. Cohen: No relevant financial relationships with ineligible companies to disclose.
S. Cox: Honoraria/Speaking/Consulting Fee: ScottCare, Inc.
B.E. Dechert-Crooks: No relevant financial relationships with ineligible companies to disclose.
J. W. Dukes: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Medtronic, Biotronik, BMS/Pfizer Alliance
L. L. Eckhardt: Honoraria/Speaking/Consulting Fee: UpToDate
A. Federowski: Honoraria/Speaking/Consulting Fee: Biotronik, Medtronic
E. Flatley: No relevant financial relationships with ineligible companies to disclose.
A. Gasparetti: No relevant financial relationships with ineligible companies to disclose.
E. Gerstenfeld: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Medtronic, Abbott, Boston Scientific. Research (Contracted Grants for PIs and Named Investigators Only): Biosense Webster, Inc., Farapulse
R. Gopinathannair: Honoraria/Speaking/Consulting Fee: Abbott, Biosense Webster, Inc., Boston Scientific, Zoll Medical Corporation, Sanofi, Pfizer, Inc., Biotronik, Academy for Continued Healthcare Learning
R. Hipp: Honoraria/Speaking/Consulting Fee: BioTel, Medtronic, Inc.
R. Ho: Honoraria/Speaking/Consulting Fee: Abbott, Boston Scientific
E. S. Kaufman: No relevant financial relationships with ineligible companies to disclose.
M. Leal: No relevant financial relationships with ineligible companies to disclose.
J. Liang: Honoraria/Speaking/Consulting Fee: Biotronik Abbott
D. Lin: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., BioTelemetry
H. MacLeod: No relevant financial relationships with ineligible companies to disclose.
M. Maron: Honoraria/Speaking/Consulting Fee: Cytokinetics. Research (Contracted Grants for PIs and Named Investigators Only): iRhythm Technologies, Celltrion, Takeda, Imbria
C. Miyake: No relevant financial relationships with ineligible companies to disclose.
J. P. Moore: No relevant financial relationships with ineligible companies to disclose.
M. Olen: No relevant financial relationships with ineligible companies to disclose.
B. Olshansky: Honoraria/Speaking/Consulting Fee: Boehringer Ingelheim, Amarin, Lundbeck
L. Ottobani: No relevant financial relationships with ineligible companies to disclose.
A. R. Patel: No relevant financial relationships with ineligible companies to disclose.
T. Parham: No relevant financial relationships with ineligible companies to disclose.
L. K. Racenet: No relevant financial relationships with ineligible companies to disclose.
M. Robinson: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Biotronik, Abbott, Medtronic, Inc., Boston Scientific. Research (Contracted Grants for PIs and Named Investigators Only): Abbott, Medtronic
J. Romero: Honoraria/Speaking/Consulting Fee: Sanofi. Research (Contracted Grants for PIs and Named Investigators Only): Biosense Webster, Inc. 
L.A. Rousseau: Honoraria/Speaking/Consulting Fee: Medtronic
F. Sacher: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Medtronic, Abbott, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, MicroPort, inHEART
E. Sauser: No relevant financial relationships with ineligible companies to disclose.
R. D. Schaller: Honoraria/Speaking/Consulting Fee: Medtronic, Abbott
M. Scheinman: Honoraria/Speaking/Consulting Fee: Abbott, Biosense Webster, Inc., Biotronik
W. Shen: No relevant financial relationships with ineligible companies to disclose.
P. J. Schwartz: Honoraria/Speaking/Consulting Fee: Amgen
J. Sobacki: No relevant financial relationships with ineligible companies to disclose.
R. Sutton: Honoraria/Speaking/Consulting Fee: Medtronic. Speakers' Bureau: Abbott. Stocks - Publicly Traded: Boston Scientific, Edwards Lifesciences
W. Tzou: Honoraria/Speaking/Consulting Fee: Medtronic, Biosense Webster, Inc., BioSig, Abbott, Boston Scientific, Biotronik
T. J. Walker: No relevant financial relationships with ineligible companies to disclose.
E. Walsh: No relevant financial relationships with ineligible companies to disclose.
R. Weiss: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Abbott, Impulse Dyanmics USA, Biotronik. Fellowship Support: Abbott, Medtronic, Biotronik, Biosense Webster, Inc., Boston Scientific
A. Yaeger: No relevant financial relationships with ineligible companies to disclose.
S. Zieroth: Honoraria/Speaking/Consulting Fee: Servier, Abbott, Akcea, AstraZeneca, Amgen, Alynylam Pharmaceuticals, MSD/Bayer Virtual Global Advisory Board Member, Boehringer Ingelheim, Eli Lilly

Staff (note: Staff are not directly responsible for the planning or the content of educational activities. Disclosures are provided as a matter of transparency only):

S. Alfano: No relevant financial relationships with ineligible companies to disclose.
M. Anderson: No relevant financial relationships with ineligible companies to disclose.
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
P. Magnani: No relevant financial relationships with ineligible companies to disclose.
K. Quille: Honoraria/Speaking/Consulting Fee: Pfizer, Inc. Salary from Employment: Biosense Webster, Inc.

Content Reviewers:

B. Afolabi: No relevant financial relationships with ineligible companies to disclose.
M. R. Afzal: Honoraria/Speaking/Consulting Fee: Abbott Medical
D. Alexander: No relevant financial relationships with ineligible companies to disclose.
M. Berger: No relevant financial relationships with ineligible companies to disclose.
S. Brancato: No relevant financial relationships with ineligible companies to disclose.
J. Chyou: Honoraria/Speaking/Consulting Fee: Medtronic, Inc.
T. Crawford: No relevant financial relationships with ineligible companies to disclose.
F. Del Carpio Munoz: No relevant financial relationships with ineligible companies to disclose.
R. Dendi: No relevant financial relationships with ineligible companies to disclose.
A. Elsharkawi: No relevant financial relationships with ineligible companies to disclose.
A. Elvan: Research (Contracted Grants for PIs and Named Investigators Only): Medtronic, Boston Scientific, Abbott
J. Gabriels: No relevant financial relationships with ineligible companies to disclose.
S. Gautam: No relevant financial relationships with ineligible companies to disclose.
A. Hussein: No relevant financial relationships with ineligible companies to disclose.
M. Infeld: Honoraria/Speaking/ConsultingFee: Biosense Webster, Inc.
L. Jackson, II: Honoraria/Speaking/Consulting Fee: Medtronic, Biosense Webster, Inc., Medscape, Zoll Medical Corporation, Johnson and Johnson
S. Karim: No relevant financial relationships with ineligible companies to disclose.
P. Karpawich: No relevant financial relationships with ineligible companies to disclose.
H. Kawata: Honoraria/Speaking/Consulting Fee: Biotronik
I. Koniari: No relevant financial relationships with ineligible companies to disclose.
P. LeLorier: Honoraria/Speaking/Consulting Fee: Medtronic; Fellowship Support: Biotronik, Abbott
D. Lin: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., BioTelemetry, Abbott Medical
S. Majumdar: No relevant financial relationships with ineligible companies to disclose.
T. McGarry: No relevant financial relationships with ineligible companies to disclose.
T. Moukabary: No relevant financial relationships with ineligible companies to disclose.
S. Mountantonakis: Honoraria/Speaking/Consulting Fee: Medtronic, Biotronik
M. Nageh: No relevant financial relationships with ineligible companies to disclose.
B. Olshansky: Honoraria/Speaking/Consulting Fee: Lundbeck, Boehringer Ingelheim, Amarin
R. Schreier: No relevant financial relationships with ineligible companies to disclose.
K. Srivasthasn: Honoraria/Speaking/Consulting Fee: Abbott

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company within the 24 months prior to the disclosure.

The Heart Rhythm Society takes steps to assure its learners and the public that the content of certified activities is accurate and reliable. The following principles are applied to the process of validating CME content. The content is peer-reviewed to ensure the following:

Fair Balance - that content is balanced among various options available for treatment and not biased toward a particular product or manufacturer.

Patient Treatment Recommendations - that patient treatment recommendations contained in the content are evidence-based, are appropriate for the target audience, and that the patient treatment recommendations contribute to overall improvement in patient care.

Scientific Validity - those scientific studies cited in the activity conform to standards accepted by the scientific community.

Learning Objectives - that the educational content supports the learning objectives of the activity, and that the objectives stated for performance-in-practice are actionable and measurable.

Omissions - that no seminal studies, data, or best evidence are missing.